2023
DOI: 10.1007/s00395-023-01001-5
|View full text |Cite
|
Sign up to set email alerts
|

Rivaroxaban attenuates neutrophil maturation in the bone marrow niche

R. Schneckmann,
M. Döring,
S. Gerfer
et al.

Abstract: Pharmacological inhibition of factor Xa by rivaroxaban has been shown to mediate cardioprotection and is frequently used in patients with, e.g., atrial fibrillation. Rivaroxaban's anti-inflammatory actions are well known, but the underlying mechanisms are still incompletely understood. To date, no study has focused on the effects of rivaroxaban on the bone marrow (BM), despite growing evidence that the BM and its activation are of major importance in the development/progression of cardiovascular disease. Thus,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
references
References 72 publications
0
0
0
Order By: Relevance